{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:30:34Z","timestamp":1765279834736,"version":"3.40.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,5,22]],"date-time":"2014-05-22T00:00:00Z","timestamp":1400716800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s11095-014-1384-5","type":"journal-article","created":{"date-parts":[[2014,5,21]],"date-time":"2014-05-21T18:53:49Z","timestamp":1400698429000},"page":"2876-2886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Model Based Analysis of IPEC Dosing of Paclitaxel in Rats"],"prefix":"10.1007","volume":"31","author":[{"given":"Pieter","family":"Colin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieselotte","family":"De Smet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Vervaet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Remon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Ceelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Van Bocxlaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen","family":"Boussery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,22]]},"reference":[{"issue":"2","key":"1384_CR1","first-page":"256","volume":"40","author":"JS Spratt","year":"1980","unstructured":"Spratt JS, Adcock RA, Muskovin M, Sherrill W, Mckeown J. Clinical delivery system for intra-peritoneal hyperthermic chemotherapy. Cancer Res. 1980;40(2):256\u201360.","journal-title":"Cancer Res"},{"issue":"2","key":"1384_CR2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejogrb.2011.04.036","volume":"158","author":"PA Cascales","year":"2011","unstructured":"Cascales PA, Gil J, Galindo PJ, Machado F, Frutos IMM, Paricio PP. Heterogeneity in patients and methods. A problem for hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):361\u20132.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"7","key":"1384_CR3","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","volume":"89","author":"RL Dedrick","year":"1997","unstructured":"Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst. 1997;89(7):480\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"1384_CR4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/11598890-000000000-00000","volume":"51","author":"C Hasovits","year":"2012","unstructured":"Hasovits C, Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin Pharmacokinet. 2012;51(4):203\u201324.","journal-title":"Clin Pharmacokinet"},{"key":"1384_CR5","unstructured":"Van Der Speeten K. A pharmacokinetic and pharmacodynamic rationale for perioperative cancer chemotherapy in patients with peritoneal carcinomatosis. Uppsala University; 2010."},{"issue":"9","key":"1384_CR6","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1007\/s11095-012-0765-x","volume":"29","author":"L Smet De","year":"2012","unstructured":"De Smet L, Colin P, Ceelen W, Bracke M, Van Bocxlaer J, Remon JP, et al. Development of a nanocrystalline paclitaxel formulation for hipec treatment. Pharm Res. 2012;29(9):2398\u2013406.","journal-title":"Pharm Res"},{"key":"1384_CR7","unstructured":"Guideline on bioanalytical method validation. Guideline on bioanalytical method validation. European Medicines Agency 2012 Feb 1."},{"issue":"2","key":"1384_CR8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perls-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming. Comput Methods Prog Biomed. 2004;75(2):85\u201394.","journal-title":"Comput Methods Prog Biomed"},{"issue":"1","key":"1384_CR9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","volume":"101","author":"RJ Keizer","year":"2011","unstructured":"Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Prog Biomed. 2011;101(1):72\u20139.","journal-title":"Comput Methods Prog Biomed"},{"issue":"1","key":"1384_CR10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO. Xpose\u2014an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Prog Biomed. 1999;58(1):51\u201364.","journal-title":"Comput Methods Prog Biomed"},{"key":"1384_CR11","doi-asserted-by":"crossref","unstructured":"Soetaert K, Petzoldt T, Setzer RW. Solving differential equations in R: package deSolve. J Stat Softw. 2010;33(9).","DOI":"10.18637\/jss.v033.i09"},{"issue":"3","key":"1384_CR12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/pst.449","volume":"10","author":"T Jaki","year":"2011","unstructured":"Jaki T, Wolfsegger MJ. Estimation of pharmacokinetic parameters with the R package PK. Pharm Stat. 2011;10(3):284\u20138.","journal-title":"Pharm Stat"},{"issue":"2","key":"1384_CR13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s11095-004-1190-6","volume":"22","author":"M Jiko","year":"2005","unstructured":"Jiko M, Yano I, Okuda M, Inui K. Altered pharmacokinetics of paclitaxel in experimental hepatic or renal failure. Pharm Res. 2005;22(2):228\u201334.","journal-title":"Pharm Res"},{"issue":"1\u20132","key":"1384_CR14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijpharm.2006.05.046","volume":"323","author":"BC Choi","year":"2006","unstructured":"Choi BC, Choi JS, Han HK. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. Int J Pharm. 2006;323(1\u20132):81\u20135.","journal-title":"Int J Pharm"},{"issue":"9","key":"1384_CR15","first-page":"2112","volume":"56","author":"A Sparreboom","year":"1996","unstructured":"Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 1996;56(9):2112\u20135.","journal-title":"Cancer Res"},{"issue":"10","key":"1384_CR16","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2217\/fon.10.100","volume":"6","author":"Z Lu","year":"2010","unstructured":"Lu Z, Wang J, Wientjes MG, Au JLS. Intraperitoneal therapy for peritoneal cancer. Future Oncol. 2010;6(10):1625\u201341.","journal-title":"Future Oncol"},{"issue":"2","key":"1384_CR17","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0022-3565(24)34976-6","volume":"290","author":"HJ Kuh","year":"1999","unstructured":"Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JLS. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther. 1999;290(2):871\u201380.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1384_CR18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1124\/jpet.107.121632","volume":"322","author":"D Lu","year":"2007","unstructured":"Lu D, Wientjes MG, Lu Z, Au JLS. Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther. 2007;322(1):80\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"1384_CR19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","volume":"12","author":"N Desai","year":"2006","unstructured":"Desai N, Trieu V, Yao ZW, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4):1317\u201324.","journal-title":"Clin Cancer Res"},{"key":"1384_CR20","unstructured":"Gabrielsson G, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. 4th edition ed. 2007."},{"issue":"1","key":"1384_CR21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1124\/jpet.112.199109","volume":"344","author":"S Ait-Oudhia","year":"2013","unstructured":"Ait-Oudhia S, Straubinger RM, Mager DE. Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy. J Pharmacol Exp Ther. 2013;344(1):103\u201312.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1384_CR22","doi-asserted-by":"crossref","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","volume":"288","author":"MF Flessner","year":"2005","unstructured":"Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Ren Physiol. 2005;288(3):F433\u201342.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"2","key":"1384_CR23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1010662413174","volume":"19","author":"SH Jang","year":"2001","unstructured":"Jang SH, Wientjes MG, Au JLS. Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Investig New Drugs. 2001;19(2):113\u201323.","journal-title":"Investig New Drugs"},{"issue":"1","key":"1384_CR24","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1349-7006.2010.01747.x","volume":"102","author":"T Kamei","year":"2011","unstructured":"Kamei T, Kitayama J, Yamaguchi H, Soma D, Emoto S, Konno T, et al. Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules. Cancer Sci. 2011;102(1):200\u20135.","journal-title":"Cancer Sci"},{"issue":"9","key":"1384_CR25","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-06-1941","volume":"13","author":"AH Kyle","year":"2007","unstructured":"Kyle AH, Huxham LA, Yeoman DM, Minchinton AI. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res. 2007;13(9):2804\u201310.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1384_CR26","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3892\/or.2012.1650","volume":"27","author":"JH Lee","year":"2012","unstructured":"Lee JH, Na K, Song SC, Lee J, Kuh HJ. The distribution and retention of paclitaxel and doxorubicin in multicellular layer cultures. Oncol Rep. 2012;27(4):995\u20131002.","journal-title":"Oncol Rep"},{"issue":"8","key":"1384_CR27","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0959-8049(97)00114-7","volume":"33","author":"KM Nicholson","year":"1997","unstructured":"Nicholson KM, Bibby MC, Phillips RM. Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. Eur J Cancer. 1997;33(8):1291\u20138.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1384_CR28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.108.140095","volume":"327","author":"Z Lu","year":"2008","unstructured":"Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JLS. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther. 2008;327(3):673\u201382.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-014-1384-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-014-1384-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-014-1384-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:28:00Z","timestamp":1746232080000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-014-1384-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,22]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1007\/s11095-014-1384-5","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"type":"print","value":"0724-8741"},{"type":"electronic","value":"1573-904X"}],"subject":[],"published":{"date-parts":[[2014,5,22]]}}}